FDA grants setrusumab rare pediatric disease designation for treatment of osteogenesis imperfecta (OI)

OI is a rare genetic disease marked by fragile bones and decreased bone mass. Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that inhibits the activity of osteobloasts. It has been accepted into the EMA’s Priority Medicines (PRIME) scheme.

Source:

Biospace Inc.